Hovione Scientia and Consort Medical both contributed capital as Precision Cocular extended a series A round that will fund its pipeline of retinal disease treatments.
Precision Ocular, a UK-based retinal disease therapy developer, closed its series A round at £15.5m ($20.6m) today following an extension provided by V-Bio Ventures, a venture capital fund affiliated with life sciences institute VIB.
The company previously achieved an initial £13.5m close in March 2016 thanks to a consortium led by Imperial Innovations, the investment firm set up by Imperial College London.
Drug encapsulation company Hovione Scientia, contract drug developer and manufacturer Consort Medical and VC firm Neomed also contributed…